Bevacizumab is the first molecular-targeted antiangiogenic therapy to be approved by the
US FDA and EMEA and, despite the numerous clinical successes, many challenges remain …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Functional polymorphisms on the
VEGF‐A gene, known to be linked to cancer risk or to VEGF‐A plasma concentrations, have …

To investigate pharmacogenetic interactions among VEGF-A, VEGFR-2, IL-8, HIF-1α, EPAS-
1, and TSP-1 SNPs and their role on progression-free survival (PFS) in metastatic breast …

Background No biomarkers that could guide patient selection for treatment with the anti-
VEGF monoclonal antibody bevacizumab have been identified. We assessed whether …

The prospective multicenter COMET trial followed a cohort of 306 consecutive metastatic
breast cancer patients receiving bevacizumab and paclitaxel as first-line chemotherapy. This …

Recent data reported an association between VEGF-A genotype of tumors and median
overall survival as well as grade 3 or 4 hypertension when using bevacizumab in metastatic …

Background Despite extensive translational research, no validated biomarkers predictive of
bevacizumab treatment outcome have been identified. Methods We performed a meta …

e14561 Background: Vascular endothelial growth factor (VEGF) and its receptors (VEGFr-2)
have important roles in angiogenesis, predicting risk and prognosis in several solids tumor …

Biomarkers for bevacizumab efficacy in metastatic breast cancer (MBC) are of urgent need.
The genetic variability of genes involved in angiogenesis could explain the interpatient …

Agents inhibiting tumor angiogenesis have been developed as a new class of anticancer
agents (reviewed in Ref.[1]). Several of these therapeutics target the vascular endothelial …